Get 20% lifetime commission for referring investors to digrin.com here.

Kinnate Biopharma Inc. (KNTE) Financials

Stock symbol KNTE is outdated, potentially delisted? Maybe it is available on other exchange?

KNTE Assets vs Liabilities

Date	Assets	Liabilities
Sept. 30, 2023	190.7 million	18.3 million
June 30, 2023	216.1 million	18.5 million
March 31, 2023	243.9 million	21.1 million
Dec. 31, 2022	278.8 million	20.4 million

KNTE Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.

Date	Free Cash Flow	Stock based compensation
Sept. 30, 2023	-25.5 million	5.3 million
June 30, 2023	-29.4 million	5.4 million
March 31, 2023	-27.7 million	5.4 million
Dec. 31, 2022	-23.8 million	4.9 million

KNTE Net Income

No data available :(

KNTE Cash and Debt

Graph available only for paid members. Upgrade to see it.

Date	Cash	Debt	Capital Lease
Sept. 30, 2023	167.6 million	-	3.4 million
June 30, 2023	184.7 million	-	3.7 million
March 31, 2023	201.0 million	-	3.9 million
Dec. 31, 2022	201.5 million	-	4.2 million

KNTE Shares Outstanding

Graph available only for paid members. Upgrade to see it.

Date	Shares Outstanding
Sept. 30, 2023	47.1 million
June 30, 2023	46.7 million
March 31, 2023	45.4 million
Dec. 31, 2022	44.1 million

KNTE Expenses

Graph available only for paid members. Upgrade to see it.

Date	Capex	R&D	G&A	S&M
Sept. 30, 2023	-	24.5 million	6.6 million	-
June 30, 2023	9000	26.3 million	7.8 million	-
March 31, 2023	9000	26.6 million	8.1 million	-
Dec. 31, 2022	90000	25.2 million	7.5 million	-

KNTE Cost of Revenue

Graph available only for paid members. Upgrade to see it.

Date	Revenue	Cost of Revenue
Sept. 30, 2023	-	197000
June 30, 2023	-	201000
March 31, 2023	-	203000
Dec. 31, 2022	-	190000

KNTE

Price: $2.65

52 week price:

1.04

7.19

Earnings Per Share: -2.78 USD

P/E Ratio: -0.84

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 55200

Market Capitalization: 125.0 million

Links:

KNTE on Yahoo Finance